Slides Presented During Q & A. Expected Events in Untreated Patients Over 5 Years a Taiwan Observational Cohort Study and Safety Cohort b Chen CJ et al.

Slides:



Advertisements
Similar presentations
Bruix J, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 24, 2009, Copenhagen, Denmark.04/28/09.
Advertisements

Professor George KK Lau The University of Hong Kong Hong Kong SAR, China HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated.
Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.
INTELENCE (Etravirine) UPDATE Global Clinical Research Rekha Sinha, MD January 30, 2009.
Updates in HBV Management CCO Independent Conference Coverage of the 2006 Annual Meeting of the European Association for the Study of the Liver* April.
Stephanos HADZIYANNIS. Following HBeAg seroconversion a proportion of patients retains or redevelops significant HBV replication associated with persistent.
3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.
1 FDA Advisory Meeting Clinical Trial Design – Hepatitis B Treatment Anna S.F. Lok, M.D. University of Michigan Ann Arbor, M I.
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
1 Roadmap for Management of Patients with Chronic Hepatitis B (CHB) Prof. Xinxin Zhang Rui Jin Hospital Jiao Tong University.
Global HIV Resistance: The Implications of Transmission
Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
1 FDA Review Perspective – Entecavir for Hepatitis B Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products.
Nebojsa Mirkovic, Carles Ferrer-Costa, Marc A. Marti-Renom, Alvaro N.A. Monteiro, Andrej Sali Functional Consequences of the SNPs : BRCA1, Membrane Transporters.
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA (Options in Management with Antiretrovirals) Trial Birgitt Dau, M.D. Postdoctoral.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia.
NS5A and polymerase inhibitors Mark Sulkowski, MD Professor of Medicine Johns Hopkins University Baltimore Maryland
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
No HBV or HIV co-infection
SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
Switching ARVs in Virologically Suppressed Patients.
Supplemental Table 1. Primers used in Ion Torrent sequencing of HPV. Bar codes id_strSequence IonXpress_1CTAAGGTAAC IonXpress_2TAAGGAGAAC IonXpress_3AAGAGGATTC.
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24.
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
On-treatment management for chronic hepatitis B (CHB) in patients receiving oral antiviral therapy Byung-Ho Kim Kyung Hee University School of Medicine.
내과스텝강의 국내 만성B형간염의 현황과 치료 전략.
Maria Buti, MD Professor of Medicine Hospital Universitario Vall d'Hebron Barcelona, Spain Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and.
Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.
A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated.
eGFR (MDRD) > 50 mL/min
Treatment-Naïve Adults
Evidence-based Treatment for Hepatitis B Infection
Comparison of INSTI vs INSTI
Design No randomisation Open-label W12 W years HCV genotype 1
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3
No HBV or HIV co-infection
GEODE-II Study: OBV/PTV/r + DSV + low dose RBV in genotype 1a
Phase 3 Treatment-Naïve and Treatment-Experienced
Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and Cirrhosis
Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma CCO Independent Conference Highlights of the 2015 ASCO Annual.
HBV Management in 2012… Where Are We Heading?
ARV-trial.com Switch to MVC MARCH Study 1.
How to optimize the management of my HBeAg negative patients?
GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II
Mean ADHD-RS-IV Scores at End Point
ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB
Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B  Eugene R. Schiff, Samuel S.
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Impact of Baseline NNRTI Mutations on the Virologic Response to TMC125 in the Phase III Clinical Trials DUET-1 and DUET-2 J Vingerhoets, A Buelens, M.
No HBV or HIV co-infection
Comparison of INSTI vs INSTI
Phase 3 Treatment-Naïve and Treatment-Experienced
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Presentation transcript:

Slides Presented During Q & A

Expected Events in Untreated Patients Over 5 Years a Taiwan Observational Cohort Study and Safety Cohort b Chen CJ et al. EASL 2005, abstract 1256 c Iloeje UH. EASL 2005, abstract 1265 Non-skin Non-HCC cancers a HCC b Cirrhosis c Events / 1000 Patients 15-20

Pregnancies in ETV Clinical Program: Outcome (N = 41) Safety Update Outcome ETV N = 21 LVD N = 16 ETV / LVD N = 2 Placebo N = 2 Elective Termination Spontaneous Abortion 1301 Live Birth3120 Outcome Unknown

Substitutions Selected by ETV Study Patient Population Residues with Novel Emerging Substitutions ETV EC Nucleoside naïve, eAg+ E8G, E8Q, R18K, V23A, N33S, G52R, S57P, A62T, S75P, N76K, S78T, R110G, N118S, R120K, H124Q, L132R, L147P, Y148H, G152E, K154R, K154T, H156Y, R167Q, P170S, F178S, A181T, I187V, K212R, K212T, S219P, T222S, L229S, S230A, G232D, G232S, H234Q, K241E, W243G, S246C, G251E, C256G, P261S, I265S, R274G, K275E, I278M, V278L, I282L, K285N, K285T, I290L, C303Y, I315V, N337I, V341I WT levels nM 027 Nucleoside naïve, eAg- D2N, H9R, R18S, N33T, N71D, S78Y, S78T, D83G, V84M, S117Y, I121S, Q125K, M129T, R153L, A194S, T222S, H234R, R270E, K275N, R280K, W284Stop, R289Q, G292D, F296L, I315L, K318R, A320T, M336I, A342T WT levels 0.8 – 12 nM 014 LVD Refractory L80I, L229W LVD R levels 22 – 45 nM 026 LVD Refractory V27A, I53F, S78T, L80V, K168E, A181T, C188S, V191A, A200V, V224A, D263G, G295S, M309L LVD R levels 2.4 – 31 nM 13-15

ETV Virologic Rebounds: Year Two Study022 eAg pos 027 eAg neg YR 1 Treated YR 2 Treated YR 1 Rebounds 6 (2%) 5 (2%) YR 2 Rebounds 6 (2%) 1 (<1%) Genotypic Resistance* 0 (0%) ETVLVD n = Wk Wk HBV DNA (Copies/mL) 10 3 < Percent of Subjects Study 022 eAg pos Study

Knodell Necroinflammatory Mean Score Naïve eAg+ Naïve eAg- LVD-Ref eAg+ ETV N = 292 LVD N = 269 ETV N = 265 LVD N = 250 ETV N = 110 LVD N = 98 Baseline Week Week 48 change from baseline * -3.2* -2.9 * 0.6 * Analyses were based on patients with baseline Knodell necroinflammatory score ≥ 2 and adequate Week 48 biopsy * p < 0.01 (ETV vs. LVD) Studies 022, 027 and

Sustained Response Through 24 Weeks Off Treatment for Responders at Week 48 – Naïve Patients Studies 022 and 027 Naïve eAg+ Naïve eAg- Percent N = LVD ETV n = 61n = 49 n = 124n =

Histologic Improvement, HBV DNA, and ALT at Week 48 Studies 022, 027 and 026 Naïve eAg+ Naïve eAg- LVD-Ref eAg+ ETV N = 314 LVD N = 314 ETV N = 296 LVD N = 287 ETV N = 124 LVD N = 116 Histologic Improvement, ALT ≤ 1 x ULN and HBV DNA < 400 copies/mL 138 ( 44) 80 ( 25) ( 25)170 ( 57) 112 ( 39) ( 39)16 ( 13) 0 ( 0) Histologic Improvement, ALT ≤ 1 x ULN and HBV DNA < 10 5 copies/mL 169 ( 54) 122 ( 39) ( 39)179 ( 60) 130 ( 45) ( 45)29 ( 23) 1 ( 1) Evaluable Baseline Histology Number of patients (%) 17-1

< >210 Doubling Time (days) Number of Cases Growth Rates of HCC Sheu J-C et al, Gastro 1985;89:259 Median doubling time = 117 days (range )

Start of Therapy Tumor Volume (cc) Months Six cases of HCC Origin Relative to Start of Therapy – Doubling Time 29 d 3E 2L 1L 4E5E 6L

Start of Therapy Months Six cases of HCC Origin Relative to Start of Therapy 6L doubling time 29 d doubling time 117 d